Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized ADEBAR trial
Titel:
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized ADEBAR trial
Auteur:
Schwentner, Lukas Harbeck, Nadia Singer, Susanne Eichler, Martin Rack, Brigitte Forstbauer, Helmut Wischnik, Arthur Scholz, Christoph Huober, Jens Friedl, Thomas W.P. Weissenbacher, Tobias Härtl, Kristin Kiechle, Marion Janni, Wolfgang Fink, Visnja